Opendata, web and dolomites

BraINstorm SIGNED

Engineered nanocarriers for simultaneous anticancer immune response and “switching” of tumor-associated macrophages for intranasal glioblastoma treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BraINstorm project word cloud

Explore the words cloud of the BraINstorm project. It provides you a very rough idea of what is the project "BraINstorm" about.

tackle    biocompatibility    crossing    patient    brainstorm    care    taas    chemical    microenvironment    disease    acid    emerged    cancer    treatment    intranasal    anti    immune    resection    administration    nose    switch    therapeutic    survival    generating    barrier    size    explore    education    precludes    ex    release       m1    chemotherapy    anticancer    immunoconjugates    macrophages    oligonucleotide    standard    invasive    brain    vivo    stimulation    advantage    rate    prophylactic    combination    performed    explored    complexity    storm    regards    immunotherapeutic    drug    vitro    immunotherapy    reduces    memory    adhesivity    hyaluronic    gbm    model    lasting    physical    local    clinically    cpg    intrinsic    blood    antigen    therapies    treat    immunomodulatory    re    peptides    tam    macrophage    types    turning    conventional    m2    muco    curable    tumoral    position    route    parallel    glioblastoma    engineer    mucosa    promotes    50    effect    conjugates    radiotherapy    preliminary    infiltrated    tumor    surgery    nasal    cells    invasiveness    expansion    oligonucleotides    followed    appealing    comprise    strategy    assessing   

Project "BraINstorm" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE CATHOLIQUE DE LOUVAIN 

Organization address
address: PLACE DE L UNIVERSITE 1
city: LOUVAIN LA NEUVE
postcode: 1348
website: www.uclouvain.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 166˙320 €
 EC max contribution 166˙320 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) coordinator 166˙320.00

Map

 Project objective

Glioblastoma (GBM) remains a non-curable disease due to its high complexity and its position beyond the blood-brain barrier, which precludes access by conventional therapies. The current standard of care includes tumor resection surgery followed by radiotherapy or chemotherapy; an invasive process with a survival rate after five years is less than 5%. Tumor-associated macrophages (TAM) type 2 (M2 macrophages) comprise 30-50% of the infiltrated cells in GBM microenvironment and support tumor expansion. Immunotherapy represents an appealing strategy to treat several cancer types by turning the immune system against tumor cells; tumor antigen peptides (TAAs) recently emerged as an immunotherapeutic approach that can provide for a long-lasting immune response. Immunomodulatory oligonucleotides can “switch” M2 macrophages into M1 macrophages that produce an anti-tumoral effect. The BraINstorm (Brain INtranasal storm) project aims to engineer a hyaluronic acid (HA)-based combination conjugates that tackle GBM by the stimulation of the immune system via the delivery of TAAs and an immunomodulatory oligonucleotide (CpG) that promotes M2 macrophage “re-education” generating an “anticancer storm”. In parallel, taking advantage of the intrinsic muco-adhesivity of HA, BraINstorm will explore the nose-to-brain drug delivery, a more patient-friendly route that reduces the invasiveness. Novel combination immunoconjugates will be fully chemical-physical characterized and preliminary in vitro studies will be performed assessing the biocompatibility, drug release, and nasal mucosa barrier crossing in an ex-vivo model. Finally, the prophylactic and therapeutic activity of the HA-based conjugates will be in vivo explored in a clinically relevant GBM in vivo model through intranasal (IN) and local treatment administration with regards to effects on tumor size, immune memory, and survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSTORM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSTORM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GRAHAM (2018)

Concepts of Graph Theory Applied to the Human Microbiome

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More  

DOC-Stim (2020)

Communication and rehabilitation for people with Disorders of consciousness via Brain-Computer Interfaces

Read More